Literature DB >> 8426511

Eosinophil cationic protein in the nasal secretions of patients with mite allergic rhinitis.

K Nishioka1, C Saito, T Nagano, M Okano, Y Masuda, T Kuriyama.   

Abstract

In 25 patients with mite nasal allergy and 13 healthy control subjects, levels of eosinophil cationic protein (ECP) and histamine in nasal secretions were examined before and after challenge with mite extract. The ECP level was found to be significantly higher in the washings taken 30 minutes after challenge compared with the washings taken before challenge (P < .05). ECP levels measured both before and after mite extract challenge were found to be significantly higher in the patients than in the controls (P < .01). These facts suggest that the ECP affects the nasal mucosa by causing injury to ciliated cells and by acceleration of the processes of modification and inhibition of the allergic reaction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426511     DOI: 10.1002/lary.5541030212

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis.

Authors:  M Lauriello; P Muzi; L Di Rienzo; C Di Stanislao; G Coen Tirelli; M Bologna
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-10       Impact factor: 2.124

2.  Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis.

Authors:  Dong-Il Sun; Young-Hoon Joo; Hyeon-Jin Auo; Jun-Myung Kang
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-26       Impact factor: 2.503

3.  Concentrations of chemical mediators in nasal secretions after nasal allergen challenges in atopic patients.

Authors:  D Wang; P Clement; J Smitz; M P Derde
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

4.  Modulation of Immune Functions by Foods.

Authors:  Shuichi Kaminogawa; Masanobu Nanno
Journal:  Evid Based Complement Alternat Med       Date:  2004-10-06       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.